Listen to this article · 7 min listen

When it comes to allocating healthcare resources, algorithmic bias is a direct threat to equitable care and a major headache for digital health innovators facing new regulations and ethical questions. The problem explodes when an AI, which was supposed to optimize efficiency, ends up perpetuating societal inequities because of the proxies it’s using for data. If you’re an impact investor looking to de-risk your portfolio or a healthcare compliance officer in the weeds of an increasingly dense regulatory field, you have to understand how these systems fail.

The Peril of Proxy Variables in Care Allocation

At the heart of the problem is how these algorithms identify patients for intensive care programs, they often rely on proxy variables. These proxies look harmless on the surface, but they can be tightly correlated with race and socioeconomic status, which creates systemic gaps in care. For example, an algorithm might guess a patient’s medical need based on their predicted future healthcare costs. The assumption is that higher costs mean a sicker patient. That’s a bad assumption. The bold research from Ziad Obermeyer and his UC Berkeley team showed just how flawed it is. Their seminal 2019 study in Science dug into a commercial algorithm used across the country and found significant racial bias Obermeyer Science study on algorithmic bias. This specific algorithm, from Optum, used healthcare spending as a proxy for how sick a person was. What the researchers found was shocking: for any given risk score the algorithm produced, Black patients were significantly sicker than white patients but were assigned lower scores. This meant Black patients were less likely to get enrolled in high-touch care management programs, even when they needed them more. The study wasn’t just theoretical. They ran the numbers and found that correcting the bias would have increased the percentage of Black patients getting extra help from 17.7% to a staggering 46.5%. The bias works in a subtle, damaging way: because Black Americans have historically faced systemic barriers to getting care, they have lower healthcare expenditures on average, even when their health is poorer, so an algorithm that mistakes low spending for low risk just ends up amplifying those deep-rooted structural inequalities.

Lessons from the Optum Algorithm Case

The Optum case should be a wake-up call for anyone developing or deploying AI in healthcare. It proves algorithms aren’t neutral. They simply mirror the data they’re trained on and the assumptions of the people who built them. For impact investors, this means you can’t just take a company’s claims at face value, you have to dig into their methodology. An equity-testing protocol can’t be a nice-to-have, it has to be part of your due diligence. The lesson here is that an algorithm sold as a tool for health equity can easily make things worse if it’s not validated against actual health needs. So what does responsible AI development look like in practice? It means you have to go beyond just checking for predictive accuracy and start actively measuring and fixing fairness issues across different demographic groups. This means you must:

  • Deconstruct Proxy Variables: Question any and all assumptions that try to link things like a person’s zip code or their past healthcare usage to their actual health needs.
  • Direct Measurement of Need: Whenever you can, train and test your algorithms on direct measures of health, like lab results or clinical assessments, instead of relying on a flawed proxy like how much care has cost in the past.
  • Bias Auditing and Mitigation: Set up continuous auditing to catch algorithmic drift. You need to make sure your models aren’t quietly developing biases over time by regularly testing for performance gaps across racial, ethnic, and socioeconomic lines.

Investor Due Diligence: Screening for Equity-Testing Protocols

For investors and compliance officers, this isn’t just an ethical issue, it’s a massive risk. If you invest in an AI health tool without checking its equity-testing protocols, you’re courting moral hazard and serious regulatory blowback. Section 1557 of the Affordable Care Act strictly prohibits discrimination in health programs, and an algorithm that results in different quality of care for different groups could put health systems and their tech vendors on the wrong side of the law, facing lawsuits and public disgrace Affordable Care Act Section 1557 guidance. If you’re doing due diligence, you have to bake questions about algorithmic fairness into your investment thesis from day one. That looks like:

  • Demanding Transparency: Don’t just accept black-box answers. Require portfolio companies to show you their data sources, their model architecture, and exactly what metrics they’re using to define and measure fairness.
  • Evidence of External Validation: Prioritize companies that have paid for independent, peer-reviewed studies of their algorithms. These studies need to focus specifically on equity outcomes, not just on whether the model is technically accurate.
  • Adherence to Health Equity Frameworks: Check that the company is building and deploying its products in line with established health equity guidelines, like the ones from the Agency for Healthcare Research and Quality (AHRQ) AHRQ health equity guidelines. AHRQ’s frameworks are a good practical guide for embedding equity into the entire health IT lifecycle.
  • Commitment to Responsible AI Governance: Find out if the company has a dedicated team or a formal process for ethical AI review. It’s a good sign if they’re intentionally including diverse perspectives (not just engineers) in the design and testing phases.

We have to move from this “unguarded” AI that just absorbs and spits back existing biases to clinically validated AI that’s built from the ground up with fairness in mind. That requires investors to get proactive and make sure their money is actually funding solutions that advance health equity instead of quietly wrecking it.

Methodology and Source Note

This analysis is built on peer-reviewed academic research, especially the work by Ziad Obermeyer and his colleagues who first documented the systemic bias in a widely used healthcare algorithm. It combines those findings with practical guidance from federal health equity frameworks, mainly from the Agency for Healthcare Research and Quality (AHRQ), to contrast documented AI failures with the principles of responsible, clinically validated AI.

Frequently Asked Questions

How can algorithmic bias in AI systems impact equitable care delivery?

Algorithmic bias can inadvertently encode and perpetuate existing societal inequities, leading to systemic disparities in healthcare resource allocation. For example, algorithms relying on proxy variables like healthcare costs can systematically disadvantage certain populations, as seen in the Optum case where Black patients were assigned lower risk scores despite being sicker, thus receiving less proactive care.

What is the primary risk associated with using proxy variables in AI algorithms for healthcare resource allocation?

The primary risk is that proxy variables, while seemingly benign, can inadvertently correlate with socioeconomic status and race, leading to biased outcomes. An algorithm equating lower historical spending with lower health risk, for instance, perpetuates and amplifies existing structural inequalities, as Black individuals have historically faced barriers to healthcare access, resulting in lower expenditure even with severe conditions.

What lessons can be learned from the Optum algorithm case regarding algorithmic bias?

The Optum case demonstrates that algorithms are not neutral; they reflect their training data and design assumptions. It highlights that algorithms intended to improve health equity can worsen it without rigorous validation against true health need. This underscores the importance of scrutinizing methodologies and implementing robust equity-testing protocols.

What specific actions should impact investors and healthcare compliance officers take to de-risk AI investments in cardiac care?

Impact investors and healthcare compliance officers should demand transparency from companies regarding data sources and fairness metrics. They should prioritize companies that have subjected their algorithms to independent validation focused on equity outcomes and verify adherence to health equity frameworks. Investing without rigorous equity-testing protocols carries significant regulatory and reputational risks, as algorithmic bias can violate non-discrimination laws like the Affordable Care Act Section 1557.